Literature DB >> 18493986

IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.

David Polchert1, Justin Sobinsky, Gw Douglas, Martha Kidd, Ada Moadsiri, Eduardo Reina, Kristyn Genrich, Swati Mehrotra, Suman Setty, Brett Smith, Amelia Bartholomew.   

Abstract

Graft versus host disease (GVHD), mediated by donor T cells, is a significant source of morbidity and mortality following allogeneic stem cell transplantation. Mesenchymal stem cells (MSC) can successfully treat ongoing graft versus host disease, presumably due to their ability to suppress donor T cell proliferation. Little is known about the potential of MSC to prevent GVHD. Here we show that bone marrow-isolated MSC can suppress the development of GVHD if given after donor T cell recognition of antigen. IFN-gamma was required to initiate MSC efficacy. Recipients of IFN-gamma(-/-) T cells did not respond to MSC treatment and succumbed to GVHD. MSC, pre-treated with IFN-gamma, became immediately active and could suppress GVHD more efficiently than a fivefold-greater number of MSC that were not activated. When given at the time of bone marrow transplantation, activated MSC could prevent GVHD mortality (100% survival, p=0.006). MSC activation was dependent on the magnitude of IFN-gamma exposure, with increased IFN-gamma exposure leading to increased MSC suppression of GVHD. Activated MSC present a new strategy for preventing GVHD using fewer MSC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493986      PMCID: PMC3021120          DOI: 10.1002/eji.200738129

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  66 in total

1.  Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.

Authors:  B R Blazar; C J Lees; P J Martin; R J Noelle; B Kwon; W Murphy; P A Taylor
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation.

Authors:  O Baud; O Goulet; D Canioni; F Le Deist; I Radford; D Rieu; S Dupuis-Girod; N Cerf-Bensussan; M Cavazzana-Calvo; N Brousse; A Fischer; J L Casanova
Journal:  N Engl J Med       Date:  2001-06-07       Impact factor: 91.245

3.  Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.

Authors:  Olle Ringdén; Mehmet Uzunel; Ida Rasmusson; Mats Remberger; Berit Sundberg; Helena Lönnies; Hanns-Ulrich Marschall; Aldona Dlugosz; Attila Szakos; Zuzana Hassan; Brigitta Omazic; Johan Aschan; Lisbeth Barkholt; Katarina Le Blanc
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

4.  Prevention of transfusion-associated graft-versus-host disease by photochemical treatment.

Authors:  J A Grass; T Wafa; A Reames; D Wages; L Corash; J L Ferrara; L Lin
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

5.  Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.

Authors:  K van Besien; A Bartholomew; W Stock; D Peace; S Devine; D Sher; J Sosman; Y H Chen; M Koshy; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

Review 6.  Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies.

Authors:  James L M Ferrara; Gregory Yanik
Journal:  Clin Adv Hematol Oncol       Date:  2005-05

7.  Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.

Authors:  John E Wagner; John S Thompson; Shelly L Carter; Nancy A Kernan
Journal:  Lancet       Date:  2005 Aug 27-Sep 2       Impact factor: 79.321

8.  Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism.

Authors:  T R Spitzer; F Delmonico; N Tolkoff-Rubin; S McAfee; R Sackstein; S Saidman; C Colby; M Sykes; D H Sachs; A B Cosimi
Journal:  Transplantation       Date:  1999-08-27       Impact factor: 4.939

9.  Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains.

Authors:  G C Kopen; D J Prockop; D G Phinney
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

10.  Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.

Authors:  F Boulad; A Gillio; T N Small; D George; V Prasad; J Torok-Castanza; A D Regan; N Collins; A D Auerbach; N A Kernan; R J O'Reilly
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

View more
  238 in total

1.  Immortalized CNS pericytes are quiescent smooth muscle actin-negative and pluripotent.

Authors:  Paula Dore-Duffy; Afroza Mehedi; Xueqian Wang; Michael Bradley; Richard Trotter; Alexander Gow
Journal:  Microvasc Res       Date:  2011-04-15       Impact factor: 3.514

Review 2.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

3.  Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.

Authors:  Jeffery J Auletta; Robert J Deans; Amelia M Bartholomew
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

Review 4.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

5.  Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells.

Authors:  M J Crop; C C Baan; S S Korevaar; J N M Ijzermans; M Pescatori; A P Stubbs; W F J van Ijcken; M H Dahlke; E Eggenhofer; W Weimar; M J Hoogduijn
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

Review 6.  Emerging therapeutic approaches for multipotent mesenchymal stromal cells.

Authors:  Paolo F Caimi; Jane Reese; Zhenghong Lee; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 7.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 8.  Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications.

Authors:  Nayoun Kim; Seok-Goo Cho
Journal:  Int J Hematol       Date:  2015-12-11       Impact factor: 2.490

9.  Adipose-Derived Stem Cells Ameliorate Experimental Murine Colitis via TSP-1-Dependent Activation of Latent TGF-β.

Authors:  Hiroshi Takeyama; Tsunekazu Mizushima; Mamoru Uemura; Naotsugu Haraguchi; Junichi Nishimura; Taishi Hata; Chu Matsuda; Ichiro Takemasa; Masakazu Ikenaga; Kohei Murata; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori
Journal:  Dig Dis Sci       Date:  2017-04-22       Impact factor: 3.199

Review 10.  Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.

Authors:  Matthew W Klinker; Cheng-Hong Wei
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.